MNAT1

MNAT1 (MAT1) is an assembly factor for the trimeric CDK-activating kinase (CAK) complex containing CDK7 and cyclin H, which associates with the TFIIH complex that operates in both transcription and DNA repair (PMID:9465303). Beyond this core role, MNAT1 has been characterized predominantly as a pro-tumorigenic regulator: it physically binds p53, enhances MDM2–p53 association, and promotes ubiquitin-dependent p53 degradation, thereby shortening p53 half-life and suppressing apoptosis to drive colorectal cancer growth (PMID:30477538). In cerebral endothelial cells, MNAT1 has a protective function, stabilizing the necroptosis regulator A20 and the Aβ-export component LRP1β against lysosomal degradation, so that its loss provokes blood–brain barrier damage, necroptosis, and Aβ accumulation (PMID:33296651). Its own transcription is epigenetically activated by SMYD2-catalyzed H3K36me2 deposition at the MNAT1 promoter (PMID:37232506).

1. 1998 Medium

   Established MNAT1 as the assembly-factor subunit (MAT1) of the CDK7–cyclin H CAK complex and placed the gene at chromosome 14q23, anchoring its identity in the transcription/DNA-repair machinery via TFIIH.

   Evidence FISH, somatic cell hybrid analysis, and YAC contig mapping; CAK composition from biochemical literature

   PMID:9465303

   Open questions at the time

   • Does not provide functional dissection of MNAT1's role within CAK beyond cited context
   • No structural basis for assembly defined here
2. 2018 Medium

   Answered how MNAT1 promotes cancer cell survival by showing it physically binds p53 and accelerates its MDM2-dependent degradation, linking MNAT1 to apoptosis suppression independent of its canonical CAK role.

   Evidence Co-immunoprecipitation, p53 half-life Western blot, apoptosis flow cytometry, colony formation, and xenograft in colorectal cancer cells

   PMID:30477538

   Open questions at the time

   • Mechanism by which MNAT1 enhances MDM2–p53 binding not structurally resolved
   • Relationship to CAK/TFIIH function unaddressed
3. 2020 Low

   Extended MNAT1's oncogenic role to PI3K/Akt/mTOR signaling, indicating it promotes proliferation and chemoresistance through a growth-signaling axis.

   Evidence siRNA knockdown, effector Western blots, proliferation/invasion assays, and xenograft in osteosarcoma cells

   PMID:33272245

   Open questions at the time

   • Pathway placement rests on downstream effector blotting without reconstitution or rescue
   • Direct molecular link between MNAT1 and PI3K not established
4. 2020 Medium

   Revealed a protective, tissue-specific function distinct from cancer contexts: MNAT1 stabilizes A20 and LRP1β against lysosomal degradation in cerebral endothelium to prevent necroptosis and maintain Aβ clearance.

   Evidence Nat1-/- mice, AD models, AAV-mediated rescue, Western blot, BBB permeability and behavioral assays

   PMID:33296651

   Open questions at the time

   • Molecular mechanism by which MNAT1 prevents lysosomal degradation of A20/LRP1β not defined
   • Whether this requires CAK assembly activity unknown
5. 2023 Medium

   Identified an upstream regulator of MNAT1 expression, showing SMYD2-catalyzed H3K36me2 at the promoter drives MNAT1 transcription, with MNAT1 acting downstream to activate PI3K/AKT in pancreatic cancer.

   Evidence ChIP for H3K36me2, luciferase reporter, knockdown/overexpression rescue, effector Western blots, and xenograft

   PMID:37232506

   Open questions at the time

   • Direct MNAT1–PI3K mechanistic link still inferred from effector readouts
   • Generality of SMYD2 regulation across tissues untested
6. 2025 Low

   Proposed a further oncogenic effector arm in which MNAT1 binds GDF15 and modulates mitochondrial apoptosis via AMPK signaling.

   Evidence Co-immunoprecipitation, RNA-seq, ROS/JC-1/mitochondrial assays, and cisplatin xenograft in laryngeal squamous cell carcinoma

   PMID:40651179

   Open questions at the time

   • AMPK pathway placement relies on downstream readouts without reconstitution
   • GDF15 interaction lacks reciprocal/structural validation
7. 2025 Low

   Linked MNAT1 to TDP-43 proteinopathy by showing TDP-43 dysfunction generates a cryptic-exon-containing aberrant MNAT1 transcript detectable in ALS/FTD patients.

   Evidence Long- and short-read RNA-seq in iPSC-derived motor neurons with patient-sample validation

   PMID:40670663

   Open questions at the time

   • Functional consequence of the aberrant MNAT1 isoform not established
   • Whether mis-splicing alters MNAT1 protein activity unknown

• How MNAT1's canonical CAK/TFIIH assembly role mechanistically connects to its diverse context-specific functions (p53 degradation, protein stabilization, growth signaling) remains unresolved.
• No structural model linking CAK assembly to non-canonical partner binding
• Whether CAK kinase activity is required for cancer or endothelial roles untested
• Mechanism of MNAT1-dependent control of protein stability undefined